Nucleome Therapeutics Limited
12109297
Some Concerns
- Current liabilities exceed current assets (-10)
- Going concern doubt noted in accounts (-10)
Details
Compliance
Last accounts
31/12/2025
small
Next accounts due
30/09/2027
Confirmation statement
Last: 16/08/2026
Due 30/08/2027
Industry
Officers
director · Since 17/07/2019
ASSOCIATE PROFESSOR AT UNIVERSITY OF OXF
BRITISH,IRISH · UNITED KINGDOM
director · Since 30/11/2020
VENTURE CAPITALIST
BRITISH · UNITED KINGDOM
Also on 1 other board
director · Since 21/10/2022
PARTNER, PFIZER VENTURES EXECUTIVE DIREC
AMERICAN · UNITED STATES
Also on 1 other board
director · Since 21/10/2022
VENTURE CAPITALIST
DUTCH · NETHERLANDS
Also on 1 other board
Former
director · Resigned 16/10/2020
director · Resigned 19/04/2024
secretary · Resigned 26/07/2024
director · Resigned 04/12/2025
director · Resigned 04/12/2025
Persons with Significant Control
Oxford Science Enterprises Plc
Reg: 09093331 · Companies House · Corporate
Notified 02/08/2019
Former PSCs
James Raymond Hughes
Ceased 29/07/2019
Change History
Active
Private Limited Company
NUCLEOME THERAPEUTICS LIMITED, INVENTA
OXFORD
CompanyRankvs 583+ SIC 72110 peers61
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Risk deductions
Going concern doubt: -10 pts
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Going Concern Doubt
directors have identified that timing and successful completion of the planned funding represents a material uncertainty that may cast significant doubt on the company's ability to continue as a going concern. However, whilst noting this material uncertainty, the directors are of the opinion that it is appropriate to adopt the going concern basis in the preparation of the financial statements due
Key FinancialsYear ending 31/12/2025
Net Worth
£1k
Balance sheet strength
Cash
£7.7M
Cash in the bank
Net Current Assets
£10.2M
Working capital
Current Assets
£11.7M
Current Liabilities
£1.4M
Fixed Assets
£1.2M
Debtors
£4.0M
Balance Sheet
EstimatesDerived
| Year | Current Ratio |
|---|---|
| 2025 | 8.09 |
Derived from filed accounts. Not audited figures.